APOE4 predicts amyloid-β in cortical brain biopsy but not idiopathic normal pressure hydrocephalus

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 11, 2012, Pages 1119-1124

  Pyykkö, Okko T ^a   Helisalmi, Seppo ^b   Koivisto, Anne M ^a,b   Mölsä, Juhani A A ^a   Rummukainen, Jaana ^a   Nerg, Ossi ^a   Alafuzoff, Irina ^a,c   Savolainen, Sakari ^a   Soininen, Hilkka ^a,b   Jääskeläinen, Juha E ^a   Rinne, Jaakko ^a   Leinonen, Ville ^a   Hiltunen, Mikko ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; APOLIPOPROTEIN E4 GENE; ARTICLE; BRAIN BIOPSY; BRAIN VENTRICLE PERITONEUM SHUNT; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; FOLLOW UP; GAIT DISORDER; GENE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRACRANIAL PRESSURE MONITORING; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NORMOTENSIVE HYDROCEPHALUS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BIOPSY; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; MALE; MIDDLE AGED; PLAQUE, AMYLOID; PREDICTIVE VALUE OF TESTS; REGISTRIES; SENSITIVITY AND SPECIFICITY; VENTRICULOPERITONEAL SHUNT;

EID: 85027957883     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-303849     Document Type: Article

References (42)

1. Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci 1965;2:307-27.
2. Adams RD, Fischer CM, Hakim S, et al. Symptomatic occult hydrocephalus with "normal" cerebrospinal-fluid pressure. A treatable syndrome. N Engl J Med 1965;273:117-26.
3. Bergsneider M, Miller C, Vespa PM, et al. Surgical management of adult hydrocephalus. Neurosurgery 2008;62(Suppl. 2):643-59.
4. Relkin N, Marmarou A, Klinge P, et al. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005;57(3 Suppl):S4-16.
5. Marmarou A, Bergsneider M, Klinge P, et al. The value of supplemental prognostic tests for the preoperative assessment of idiopathic normal-pressure hydrocephalus. Neurosurgery 2005;57(3 Suppl):S17-28.
6. Sundstrom N, Andersson K, Marmarou A, et al. Comparison between 3 infusion methods to measure cerebrospinal fluid outflow conductance. J Neurosurg 2010;113:1294-303.
7. Leinonen V, Koivisto AM, Savolainen S, et al. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol 2010;68:446-53.
8. Eide PK, Sorteberg W. Diagnostic intracranial pressure monitoring and surgical management in idiopathic normal pressure hydrocephalus: a 6-year review of 214 patients. Neurosurgery 2010;66:80-91.
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
10. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7. (Pubitemid 27435070)
11. Thal DR, Rub U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800. (Pubitemid 34663580)
12. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44.
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. (Pubitemid 34790756)
14. Hamilton R, Patel S, Lee EB, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol 2010;68:535-40.
15. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008;65:1304-9.
16. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006;103:5644-51.
17. Zannis VI, Breslow JL, Utermann G, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982; 23:911-14. (Pubitemid 13244364)
18. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-31.
19. Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-92.
20. Nicoll JA, Savva GM, Stewart J, et al. Association between APOE genotype, neuropathology and dementia in the older population of England and Wales. Neuropathol Appl Neurobiol 2011;37:285-94.
21. Kok E, Haikonen S, Luoto T, et al. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 2009;65:650-7.
22. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
23. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-61.
24. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-53. (Pubitemid 23315843)
25. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3. (Pubitemid 23275809)
26. Strittmatter WJ, Saunders AM, Schmechel D, et al . Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81. (Pubitemid 23069980)
27. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303:1832-40.
28. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011;10:241-52.
29. Nacmias B, Tedde A, Guarnieri BM, et al. Analysis of apolipoprotein E, alpha1-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Neurosci Lett 1997;229:177-80. (Pubitemid 27316075)
30. Gudmundsson G, Kristjansdottir G, Cook E, et al . Association of ApoE genotype with clinical features and outcome in idiopathic normal pressure hydrocephalus (iNPH): a preliminary report. Acta Neurochir (Wien) 2009;151:1511-12.
31. Huttunen T, von und zu Fraunberg M, Frösen J, et al. Saccular intracranial aneurysm disease: distribution of site, size, and age suggests different etiologies for aneurysm formation and rupture in 316 familial and 1454 sporadic eastern Finnish patients. Neurosurgery 2010; 66:631-8.
32. Lehtovirta M, Soininen H, Helisalmi S, et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996;46:413-19. (Pubitemid 26081323)
33. Vepsäläinen S, Helisalmi S, Mannermaa A, et al. Combined risk effects of IDE and NEP gene variants on Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80:1268-70.
34. Savolainen S, Hurskainen H, Paljärvi L, et al. Five-year outcome of normal pressure hydrocephalus with or without a shunt: predictive value of the clinical signs, neuropsychological evaluation and infusion test. Acta Neurochir (Wien) 2002;144:515-23. (Pubitemid 34744043)
35. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental disorders. 4th edn. Washington DC: American Psychiatric Association, 1994.
37. Tsukamoto K, Watanabe T, Matsushima T, et al. Determination by PCR-RFLP of apoE genotype in a Japanese population. J Lab Clin Med 1993; 121:598-602. (Pubitemid 23112654)
38. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159-65. (Pubitemid 19239715)
39. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
40. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230-8.
41. Bertram L, McQueen M, Mullin K, et al. The AlzGene Database. Alzheimer Research Forum. http://www.alzgene.org (accessed 7 May 2011).
42. Vemuri P, Wiste HJ, Weigand SD, et al. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 2010;67:308-16.